CA Abhay Varn
@ca.abhay.varn.3790
Bihar
8+ Years of experience
SEBI Registration INH300008465I'm Abhay Kumar (also known as Abhay Varn), a Chartered Accountant who qualified at 21, with 8+ years of stock market experience, including training with large Chartered Accountancy firms. Based in Bihar, I use a framework I call Technical Fundamental GUIDE, which combines technical and fundamental analysis with five o ... Read more
Trade Ideas
29
Opinions
105
Followers
99
Expertise
Quantitative
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Live Trade Views
Posts
shared an insight ⚡️ 30 mins ago
Bosch Q2 revenue rises 28.2%, clears 1:1 bonus issue.
Bosch Limited BOSCHLTD reported Q2 revenue growth of 28.2 percent against earlier guidance of 8 percent. The board approved a 1:1 bonus issue and 5:1 stock split, subject to shareholder approval.
Q2 revenue grew 28.2 percent, well above the 8 percent guidance. The company expects flat to modest revenue growth in Q3 FY27. The board cleared a 1:1 bonus and 5:1 stock split. The strong quarter and capital actions mark a positive update for the auto component maker.
Key numbers are 28.2 percent Q2 revenue growth, the 1:1 bonus and 5:1 stock split. These may support near-term interest in the stock. Peers such as Motherson Sumi, Bharat Forge and Endurance Technologies could face relative comparison on growth and corporate actions. Risks include softer Q3 demand. Competitors listed: Motherson Sumi, Bharat Forge, Endurance Technologies. We have no financial interest in this news.
shared an insight ⚡️ 12 hours ago
Anupam Rasayan keeps FY27 EBITDA margin at 22-24%.
Anupam Rasayan India Limited ANURAS maintains its FY27 EBITDA margin guidance at 22-24 percent. It also retains medium-term organic revenue growth guidance at 20-25 percent.
H2 FY27 revenue is expected at ₹2,400-2,500 crore. This implies an annualised run rate of ₹4,800-5,000 crore. A specialty metal contract will add ₹100-150 crore in H2. The guidance supports steady growth and profitability for the specialty chemicals firm.
Key numbers are 22-24 percent EBITDA margin, 20-25 percent revenue growth, H2 revenue of ₹2,400-2,500 crore and ₹100-150 crore from the specialty metal contract. These may support near-term interest in the stock. Peers such as Aarti Industries, SRF and Navin Fluorine could face relative comparison on guidance. Risks include slower demand or cost pressures. Competitors listed: Aarti Industries, SRF, Navin Fluorine. We have no financial interest in this news.
shared an insight ⚡️ 6th Nov
Glenmark settles bulk of major US litigations.
Glenmark Pharmaceuticals Limited GLENMARK said the bulk of its major litigations in America are now settled. This removes a key overhang for the company.
Most major litigations in the US have been settled. The resolution clears a significant uncertainty for the firm. It allows management to focus more on core operations and growth in the pharma sector.
The key trigger is the settlement of the bulk of major US litigations. This may support near-term interest in the stock by reducing legal risk. Peers such as Sun Pharma, Dr. Reddy's Laboratories and Cipla could face relative comparison on litigation outcomes. Risks include any remaining cases or related costs. Competitors listed: Sun Pharma, Dr. Reddy's Laboratories, Cipla. We have no financial interest in this news.
FAQ's
What are the top stock recommendations by CA Abhay Varn?
CA Abhay Varn regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Dr. Lal Pathlabs Ltd. (Bullish), Adani Ports and Special Economic Zone Ltd. (Bullish), BSE Ltd. (Bullish), BOSCHLTD and ANURAS. Explore CA Abhay Varn's complete list of posts and trade views on their StockGro profile.
How can I follow CA Abhay Varn's latest investment insights?
You can follow CA Abhay Varn's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is CA Abhay Varn's investment strategy?
CA Abhay Varn follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has CA Abhay Varn been a SEBI-registered Research Analyst (RA)?
CA Abhay Varn has been a SEBI-registered Research Analyst and have 8+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see CA Abhay Varn's past performance and stock picks?
You can check CA Abhay Varn's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact CA Abhay Varn for stock market advice?
For stock market guidance from CA Abhay Varn, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is CA Abhay Varn's track record in predicting market movements?
CA Abhay Varn has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for CA Abhay Varn?
CA Abhay Varn is a SEBI-registered Research Analyst with the SEBI Registration INH300008465. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro